Stem Cell Therapy

In August 2011 Dr. Linda R. Elliott became trained byMedi-Vet Labratorieson a new technique involving In-House Stem Cell Therapy.In-House Stem Cell Regenerative Therapyuses ground-breaking technology to harvest adipose stem cells from the fat tissue of animals. After these cells have been extracted and activated they are injected into the arthritic joints of the animal. This is all performed while your pet is under light anesthesia.The technology created by Medi-Vet Labratories allows for the entire procedure to be completed in the hospital and all in one day.Other technologies take several days for the cells to be harvested, activated, and then injected, which also requires the animal to be under anesthesia multiple times on different days.

We are now offering in-house regenerative stem cell therapy for osteoarthritis in both dogs and cats. This is a drug free treatment that is performed in-house on a same-day basis. The procedure is proven to relieve pain and increase range of motion. Frequently, we can see treated animals walking, running and jumping as little as three weeks after the procedure. Stem cell regenerative therapy involves removing fat tissue from your pet, separating and extracting the stem cells from the fat, activating them and then injecting the stem cells into the affected joints.

The following article adapted from veterinarianDr. Tracy Lordgives a good overview:

For many of us, the term stem cell brings to mind associations with hotly debated moral and ethical issues. There is, however, another side of stem cells and stem cell therapy. I am very excited to report that stem cell therapy has arrived in the veterinary arena without controversy or contest. The process uses stem cells collected from an adult bodys own fat. Currently, we are able to offer this treatment option for dogs, cats and horses.

So how is it that an adult body still has stem cells? Stem cells are simply undifferentiated cells that can be found in most tissues in the body. These cells remain primitive or undifferentiated, waiting for the body to need them. Many people think of their bodies and cells working in a very quiet and orderly fashion. This is, however, far from reality. Our bodies are like a war zone. Inside- there is chaos and destruction everywhere. On a microscopic level, the body is constantly rebuilding just to maintain itself. Our body calls on these undifferentiated cells every day to maintain health in our organs, in bones and on the skin. Without stem cells, we could not survive.

A single stem cell is able to differentiate or turn into many different tissues such as tendon, cartilage, bone or organ depending where it goes. The controversy on the human side is over using embryonic stem cells. These cells, taken from embryos, have the ability to form whole beings- to create an entire new person, dog or sheep. Adult stem cells on the other hand, have the ability to differentiate into many different types of tissues but work to repair. This makes these cells very useful for healing tissues or potentially organs.

In animals, we now have a way to harvest adult stem cells, collect and process them and then replace them in the body where they are needed. The amazing part is that the cells take care of the rest. Stem cell therapy is also known as regenerative medicine. The cells will regenerate the tissue in its close environment.

Currently the process is open for treatment of osteoarthritis, tendon and ligament injuries, and poorly healing fractures. Once a patient has been deemed a candidate for treatment, he or she undergoes a short surgical procedure to collect fat. The fat is most often harvested from around their shoulders or pelvic area. Fat, especially from these areas, is a rich source of stem cells. In fact a small amount, less than 1/2 a cup, can potentially provide enough cells for multiple treatments for your animal. After fat collection, the stem cells are harvested and activated using an advanced patented L.E.D. technology. The number of cells harvested varies from patient to patient depending on the quality of their fat so to speak.

For the patient, the procedure involves a surgery for fat collection and then usually sedation to inject the harvested and processed cells back into joints, tendons or ligaments. If enough cells are harvested, long term CryoStorage will store those cells not needed for the first round of therapy and hold them for later use. Since the cells are autologous (supplied by the patient for its own use) there is no chance for rejection.

Studies are presently ongoing for use of this therapy in treatment of liver failure, feline kidney disease, irritable bowel syndrome and various autoimmune conditions. Thus far the procedure is most commonly used to arthritis and the results have been impressive. Decreased pain with improved mobility, a win-win combination. It is exciting to think where this therapy could lead us. What it has to offer presently, and what it could offer to our animal friends in the future.

Dr. Linda R. Elliott is accredited to perform Stem Cell Therapy at Ahwatukee Commons Veterinary Hospital. If you would like to consult with Dr. Elliott on whether this service is right for your dog or cat, please feel free tomake an appointment onlineor call us.

We love hearing your stem cell success stories!Email us your storyand well post it here!

Grover is a 16 and year old Cockapoo who had torn his left cruciate ligament a year prior. Although he was having trouble getting up and around, he was able to compensate with his right rear leg and move around enough to his owners satisfaction. Then upon getting excited to greet his owner, he ruptured his right cruciate ligament. At that point, he was no longer able to get up or move around. The owners decided to have the right cruciate ligament repaired and elected to perform stem cell therapy in both stifles and hips. The day after stem cell therapy, Grover walked out of the building, although wobbly, on all four legs. Grover has continued to improve and the owners have stated on several occasions that they now have to chase him.

From Grovers family:

Surgery sucks! While it often solves a very serious problem, the energy required to recover post-surgery is often much more difficult than one ever expects. This is especially true for both pets and their owners.

We hoped to never have to put our dog through another surgery. At his age (16) there is a risk that he may not wake up from the anesthesia, that the recovery from a surgery will be more than his body can handle, or that the emotional suffering of watching our animal in pain is more than we can bare.

That was our hope; unfortunately it was not to be. About eight weeks ago Grover, in a rush to beat me to breakfast, blew out his ACL. He already had blown out one ACL when he was younger but learned to compensate without surgery. This time, there would be no learning to compensate. Having one weak leg, plus one nearly useless leg left us with a 2 legged dog.

Our veterinarian, Dr. Elliott, informed us we had three options: that we could see if he could learn to compensate, we could have surgery to repair the ACL, or we could say goodbye. To be honest, none of these options were particularly pleasant. Dr. Elliott was able to make our decision process a little easier by talking to us about stem cell therapy and how including it as part of the surgery process could significantly improve the quality of Grovers life post-surgery and make his recovery much quicker.

We opted for a set of surgeries that included an ACL repair, a knee repair (unexpected), a growth removal, and the stem cell therapy. This meant Grover had 36 stitches when all was said and done. The surgeries were all a success.

I am writing this on Saturday the 4th of August, roughly six weeks after Grovers surgery and coincidentally my 8th wedding anniversary. Other than the odd haircut, if you saw Grover today you would never know what he has been through. Five days after surgery he was ready to run, eight days after surgery we were no longer able to keep him quiet and penned up. Two weeks after surgery all he had was a shake in his leg and today he is moving like he did before his surgery.

While I am not sure how far we have set back the clock, I can tell you that the stem cell therapy did wonders in helping our dog recover in record time. According to the veterinarian, Grover is at the three to four month point for a normal animal recovering from a similar surgery. We would like to thank Dr. Elliott and her staff for providing us with such a wonderful anniversary gift.

Here is the original post:
Pet Stem Cell Therapy Near Me 85044 - Phoenix, AZ Veterinarian

Article By Kim Ribbink.

Stem cell research often conjures images of political firestorms and futuristic science, yet its a field thats already offering hope for humans and dogs alike. While the ideal of fixing spinal injuries and curing disease may be a long way off, dogs treated with stem cells are enjoying a new lease on life.

Pepper, a 10-year-old standard poodle, is a case in point. Crippled with arthritis in both his hips, Pepper came to James Gaynor, DVM, M.S., medical director of Animal Anesthesia & Pain Management Center in Colorado Springs, Colo., with his owners, who fully expected to have to put their pet to sleep. Conventional treatments hadnt worked, or had made their dog even sicker. In fact, Peppers owners were so certain nothing could be done that they bought another puppy. At our 60 day recheck, the owner was hugging me and crying out of happiness because, in her words, we gave her back her dog, Dr. Gaynor says. The only problem was she now had Pepper and a puppy.

Healthy BonesIt wasnt long ago that dogs like Pepper with arthritis had few options beyond conventional anti-inflammatory treatments including a variety of non-steroid anti-inflammatory drugs (NSAIDs) such as Metacam, Previcox, Rimadyl and phenylbutazone; steroid medications such as Prednisone; and disease-modifying osteoarthritis drugs (DMOADs) such as Adequan Canine that sometimes dont work. Now stem cells are providing an alternative. One California-based company, Vet-Stem, uses stem cells from dogs own fat to treat animals in pain.

According to Julie Ryan Johnson, DVM, vice president of sales and marketing, studies have shown that fat is very rich with stem cells, making it an ideal source, and one that is nearly free from controversy, given that most of us dont mind having a bit of fat removed. The way we do this is a veterinarian will send us a sample of the dogs fat, Dr. Ryan Johnson says. We isolate the stem cells from that and then send the stem cells back to the veterinarian who injects them back into the dog for example, into an arthritic hip or elbow.

Once in the dog, the stem cells communicate with other cells in their environment. While its not known exactly how they work, they do decrease the dogs pain level. Its provided the veterinarian with another solution for helping these animals that have pain or difficulty moving, Dr. Ryan Johnson says. Most importantly, for the dog and the dog owner, it offers quality of life.

The PossibilitiesRichard Vulliet, Ph.D., DVM, professor and director of the Laboratory of Veterinary Cytotherapeutics at UC Davis, says stem cells havent cured any diseases yet, but researchers are working hard to change that. I think that stem cells in general will rewrite the medical textbooks in the next 10 to 20 years, Dr. Vulliet says. They will have an impact on human, canine, feline and equine health and will allow us to treat diseases that we can only dream about at this time.

Tony Kremer, DVM, an Illinois-based veterinary surgeon, says that as research progresses into the origin of diseases, there is hope that stem cell therapy might one day be used to treat diabetes and muscular dystrophy in dogs. It is hoped that this research can repair or replace diseased organs, severed spinal cords, or brain cells destroyed by Alzheimers disease in humans and dogs, he says.

Dr. Vulliet works with adult bone marrow stem cells to investigate potential cures for diseases that cause misery for many dogs. Your dog may soon be able to get breakthrough treatment in the following areas:

In the past several years, we have developed methods for recovering a therapeutic amount of bone marrow stem cells and safe, relatively non-intrusive methods for administering the cells, he says. We are now starting to enroll patients in these areas. In terms of fat-derived stem cells, progress has been made in several areas of canine health, including muscle inflammation and a disease known as immune-mediated anemia, which is when the immune system destroys red blood cells, leaving your dog weak and listless.

There has been a lot of excitement over umbilical cord blood banks centers that collect and store the blood from the placenta and umbilical cord after birth as a future source for blood stem cells but dont expect that to translate to the dog world anytime soon. When the puppies are born, you would have to match that umbilical cord to the puppy and that might be a little complicated since there are often multiple puppies in a litter, Dr. Ryan Johnson says.

Taking the PlungeIf you are going to consider stem cell therapy for your dog, it pays to think ahead. The fat in the abdomen holds stem cells so my recommendation is if, for example, a female dog is going to be spayed, as long as someone is in there, grab that fat, ship it to the lab and bank those stem cells, Dr. Gaynor says.

Youll also want to think about the risks involved in putting your dog through stem cell therapy. Dr. Vulliet says putting safety first is the primary concern. After it was found that injecting stem cells into the coronary arteries of university-owned dogs created mini heart attacks, the procedures were stopped until the technique had been improved.

According to Dr. Gaynor, there are three things to consider. The first is the same as any operation the general risks associated with anesthesia needed to perform the procedure. But there always is some anesthesia risk, especially as patients get older and sicker, but we can minimize that with good anesthesia, he says. The second is the risk posed by the surgery itself. The biggest health threat he has seen is fluid pockets forming at the site of the surgery, which is a relatively minor problem.

Finally, there are the stem cells themselves. Because they are the dogs own stem cells, theres virtually no risk, he says. The biggest thing weve seen is a few dogs whose nails grow faster than expected; thats as bad as it seems to get. With the benefits likely outweighing the risks, theres a good chance that many dog owners, perhaps even you, will be exploring canine stem cell treatments in the not-too-distant future.

Kim Ribbink is a freelance writer and editor based in Perth, Australia, who specializes in health care and the life sciences, as well as pets. She has been a journalist for 20 years, working for magazines, newspapers and online publications covering a broad range of topics.

See more here:
Pet World Insider Article - Stem Cell Research and Your Dog

Stem Cells and the Degenerate Joint

The Adicell procedure utilises adult stem cells as opposed to the controversial embryonic stem cells. Adult stem cells are found in particularly large numbers in fatty tissue. These stem cells have the ability to differentiate into connective tissue cell types, providing support and affecting the immune response, providing an anti-inflammatory effect.

You might expect that the improvement seen is the result of regeneration of the articular cartilage, however the response to treatment in dogs is so rapid that it is more likely to be due to the anti-inflammatory effects of the stem cells. The prolonged duration of effect is thought to be a consequence of the cells ability to implant within the joint as well as their capacity for self renewal.

During the Adicell procedure 20-40 g of fat is harvested from the groin area under general anaesthesia. This fat is processed in our inhouse laboratory to isolate the stem cells which are injected back into affected joints. The Adicell procedure allows us to harvest sufficient cells to treat multiple joints at the same time with no extra cost. For this reason we recommend all Adicell candidates have a full series of screening xrays taken to identify subclinically affected osteoarthritic joints that would benefit from treatment.

If you think your pet may be candidate for stem cell therapy please dont hesitate to phone us for further information.

The rest is here:
Stem Cell Treatment - Westvets Veterinary Practice

Scientists at Harvard are claiming theyve invented a new wool-like fabric that changes shape and, if I am being utterly trustworthy, I am nonetheless attempting to wrap my head round it. First off, how the hell can a cloth have a reminiscence and, secondly, what does that even imply?

A submit on Harvards website uses hair as a metaphor in an try to make clear. If you happen to straighten your hair and your hair will get moist within the rain it will definitely goes again to its authentic form, whether or not that is curly or wavy or no matter.

Subscribe to the CNET Now publication for our editors picks of an important tales of the day.

Apparently that is as a result of hair has form reminiscence.

Researchers on the Harvard John A. Paulson Faculty of Engineering and Utilized Sciences (SEAS) have created a fibrous materials that does a lot the identical factor. The hope? This new materials could possibly be utilized in garments to assist cut back waste within the vogue business. The instance the Harvard article makes use of: a one-size all suits t-shirt that might mechanically shrink or develop to suit to an individuals particular measurements. Or how about self-fitting bras or underwear?

The key is keratin, a protein present in hair and nails. The scientists took keratin from recycled wool and 3D printed the fabric into particular shapes. The above video reveals one keratin sheet, 3D printed into an origami star, scrunched up, then positioned into water. Slowly it transforms again into one thing resembling its authentic form.

This makes the fabric appropriate for an unlimited vary of purposes from textile to tissue engineering, mentioned Luca Cera, a bioengineer at Harvard and writer on the paper.

With this venture, now we have proven that not solely can we recycle wool however we are able to construct issues out of the recycled wool which have by no means been imagined earlier than, added Package Parker, the senior writer on the paper. The implications for the sustainability of pure sources are clear. With recycled keratin protein, we are able to just do as a lot, or extra, than what has been executed by shearing animals thus far and, in doing so, cut back the environmental influence of the textile and vogue business.

You possibly can learn the total examine here.

Original post:
Harvard scientists invented a material that 'remembers' its shape - Best gaming pro

LOS ANGELES, United States: Considering the growth of the global market, QY Research has recently published a report, titled Global Canine Stem Cell Therapy Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Canine Stem Cell Therapy market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Canine Stem Cell Therapy market include: VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet Canine Stem Cell Therapy

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1916703/global-canine-stem-cell-therapy-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Canine Stem Cell Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Canine Stem Cell Therapy Market Segment By Type:

Allogeneic Stem CellsAutologous Stem cells Canine Stem Cell Therapy

Global Canine Stem Cell Therapy Market Segment By Application:

Veterinary HospitalsVeterinary ClinicsVeterinary Research Institutes

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Canine Stem Cell Therapy market.

Key companies operating in the global Canine Stem Cell Therapy market include VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet Canine Stem Cell Therapy

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1916703/global-canine-stem-cell-therapy-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Canine Stem Cell Therapy Revenue1.4 Market by Type1.4.1 Global Canine Stem Cell Therapy Market Size Growth Rate by Type: 2020 VS 20261.4.2 Allogeneic Stem Cells1.4.3 Autologous Stem cells1.5 Market by Application1.5.1 Global Canine Stem Cell Therapy Market Share by Application: 2020 VS 20261.5.2 Veterinary Hospitals1.5.3 Veterinary Clinics1.5.4 Veterinary Research Institutes1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Canine Stem Cell Therapy Market Perspective (2015-2026)2.2 Global Canine Stem Cell Therapy Growth Trends by Regions2.2.1 Canine Stem Cell Therapy Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Canine Stem Cell Therapy Historic Market Share by Regions (2015-2020)2.2.3 Canine Stem Cell Therapy Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Canine Stem Cell Therapy Market Growth Strategy2.3.6 Primary Interviews with Key Canine Stem Cell Therapy Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Canine Stem Cell Therapy Players by Market Size3.1.1 Global Top Canine Stem Cell Therapy Players by Revenue (2015-2020)3.1.2 Global Canine Stem Cell Therapy Revenue Market Share by Players (2015-2020)3.1.3 Global Canine Stem Cell Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Canine Stem Cell Therapy Market Concentration Ratio3.2.1 Global Canine Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Canine Stem Cell Therapy Revenue in 20193.3 Canine Stem Cell Therapy Key Players Head office and Area Served3.4 Key Players Canine Stem Cell Therapy Product Solution and Service3.5 Date of Enter into Canine Stem Cell Therapy Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Canine Stem Cell Therapy Historic Market Size by Type (2015-2020)4.2 Global Canine Stem Cell Therapy Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Canine Stem Cell Therapy Market Size by Application (2015-2020)5.2 Global Canine Stem Cell Therapy Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Canine Stem Cell Therapy Market Size (2015-2020)6.2 Canine Stem Cell Therapy Key Players in North America (2019-2020)6.3 North America Canine Stem Cell Therapy Market Size by Type (2015-2020)6.4 North America Canine Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe7.1 Europe Canine Stem Cell Therapy Market Size (2015-2020)7.2 Canine Stem Cell Therapy Key Players in Europe (2019-2020)7.3 Europe Canine Stem Cell Therapy Market Size by Type (2015-2020)7.4 Europe Canine Stem Cell Therapy Market Size by Application (2015-2020) 8 China8.1 China Canine Stem Cell Therapy Market Size (2015-2020)8.2 Canine Stem Cell Therapy Key Players in China (2019-2020)8.3 China Canine Stem Cell Therapy Market Size by Type (2015-2020)8.4 China Canine Stem Cell Therapy Market Size by Application (2015-2020) 9 Japan9.1 Japan Canine Stem Cell Therapy Market Size (2015-2020)9.2 Canine Stem Cell Therapy Key Players in Japan (2019-2020)9.3 Japan Canine Stem Cell Therapy Market Size by Type (2015-2020)9.4 Japan Canine Stem Cell Therapy Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Canine Stem Cell Therapy Market Size (2015-2020)10.2 Canine Stem Cell Therapy Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Canine Stem Cell Therapy Market Size by Type (2015-2020)10.4 Southeast Asia Canine Stem Cell Therapy Market Size by Application (2015-2020) 11 India11.1 India Canine Stem Cell Therapy Market Size (2015-2020)11.2 Canine Stem Cell Therapy Key Players in India (2019-2020)11.3 India Canine Stem Cell Therapy Market Size by Type (2015-2020)11.4 India Canine Stem Cell Therapy Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Canine Stem Cell Therapy Market Size (2015-2020)12.2 Canine Stem Cell Therapy Key Players in Central & South America (2019-2020)12.3 Central & South America Canine Stem Cell Therapy Market Size by Type (2015-2020)12.4 Central & South America Canine Stem Cell Therapy Market Size by Application (2015-2020) 13 Key Players Profiles13.1 VETSTEM BIOPHARMA13.1.1 VETSTEM BIOPHARMA Company Details13.1.2 VETSTEM BIOPHARMA Business Overview13.1.3 VETSTEM BIOPHARMA Canine Stem Cell Therapy Introduction13.1.4 VETSTEM BIOPHARMA Revenue in Canine Stem Cell Therapy Business (2015-2020))13.1.5 VETSTEM BIOPHARMA Recent Development13.2 Cell Therapy Sciences13.2.1 Cell Therapy Sciences Company Details13.2.2 Cell Therapy Sciences Business Overview13.2.3 Cell Therapy Sciences Canine Stem Cell Therapy Introduction13.2.4 Cell Therapy Sciences Revenue in Canine Stem Cell Therapy Business (2015-2020)13.2.5 Cell Therapy Sciences Recent Development13.3 Regeneus13.3.1 Regeneus Company Details13.3.2 Regeneus Business Overview13.3.3 Regeneus Canine Stem Cell Therapy Introduction13.3.4 Regeneus Revenue in Canine Stem Cell Therapy Business (2015-2020)13.3.5 Regeneus Recent Development13.4 Aratana Therapeutics13.4.1 Aratana Therapeutics Company Details13.4.2 Aratana Therapeutics Business Overview13.4.3 Aratana Therapeutics Canine Stem Cell Therapy Introduction13.4.4 Aratana Therapeutics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.4.5 Aratana Therapeutics Recent Development13.5 Medivet Biologics13.5.1 Medivet Biologics Company Details13.5.2 Medivet Biologics Business Overview13.5.3 Medivet Biologics Canine Stem Cell Therapy Introduction13.5.4 Medivet Biologics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.5.5 Medivet Biologics Recent Development13.6 Okyanos13.6.1 Okyanos Company Details13.6.2 Okyanos Business Overview13.6.3 Okyanos Canine Stem Cell Therapy Introduction13.6.4 Okyanos Revenue in Canine Stem Cell Therapy Business (2015-2020)13.6.5 Okyanos Recent Development13.7 Vetbiologics13.7.1 Vetbiologics Company Details13.7.2 Vetbiologics Business Overview13.7.3 Vetbiologics Canine Stem Cell Therapy Introduction13.7.4 Vetbiologics Revenue in Canine Stem Cell Therapy Business (2015-2020)13.7.5 Vetbiologics Recent Development13.8 VetMatrix13.8.1 VetMatrix Company Details13.8.2 VetMatrix Business Overview13.8.3 VetMatrix Canine Stem Cell Therapy Introduction13.8.4 VetMatrix Revenue in Canine Stem Cell Therapy Business (2015-2020)13.8.5 VetMatrix Recent Development13.9 Magellan Stem Cells13.9.1 Magellan Stem Cells Company Details13.9.2 Magellan Stem Cells Business Overview13.9.3 Magellan Stem Cells Canine Stem Cell Therapy Introduction13.9.4 Magellan Stem Cells Revenue in Canine Stem Cell Therapy Business (2015-2020)13.9.5 Magellan Stem Cells Recent Development13.10 ANIMAL CELL THERAPIES13.10.1 ANIMAL CELL THERAPIES Company Details13.10.2 ANIMAL CELL THERAPIES Business Overview13.10.3 ANIMAL CELL THERAPIES Canine Stem Cell Therapy Introduction13.10.4 ANIMAL CELL THERAPIES Revenue in Canine Stem Cell Therapy Business (2015-2020)13.10.5 ANIMAL CELL THERAPIES Recent Development13.11 Stemcellvet10.11.1 Stemcellvet Company Details10.11.2 Stemcellvet Business Overview10.11.3 Stemcellvet Canine Stem Cell Therapy Introduction10.11.4 Stemcellvet Revenue in Canine Stem Cell Therapy Business (2015-2020)10.11.5 Stemcellvet Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the rest here:
Canine Stem Cell Therapy Market: Industry Statistics and Facts Helps to Flourish Industry Rapidly QYR | VETSTEM BIOPHARMA, Cell Therapy Sciences,...

Justin Dudoit and Christina Cyr of Habitat for Humanity Maui with the Blando family

Habitat for Humanity Maui completed two more homes in their affordable housing project in Lahaina.

Both homes are located in the Kahoma Residential Subdivision and feature two and four-bedroom floorplans ranging from 864 to 1,200 square feet. The family partners are longtime Lahaina residents and had over 44 family members and friends, in addition to community volunteers, who helped with the home-builds.

We never thought it would be possible to own a home, especially in these trying times, so this is our dream come true, said new homeowner, Lei Blando. Working with Habitat for Humanity Maui and alongside the community was an exciting experience. Weve made some lifelong friends and its been an amazing journey.

Helping to make the dream of homeownership a reality for these families is what Habitat for Humanity Maui is all about, said Yvonne McClean, Community Relations Director. We were able to bring people together to build homes, community, and hope during this pandemic and it would not have been possible without everyones help, she said.

Year to date, Habitat for Humanity Maui has completed four homes in the Kahoma Residential Subdivision and is projecting to finish this development by the end of the year.

To learn more about Habitat for Humanity Maui, or for ways you can help, contact Yvonne McClean at (808) 242-1140 or yvonne@habitat-maui.org.

comments

See the rest here:
Two Families Receive Keys to Their New Home as Part of Habitat for Humanity Mauis Housing Program - Maui Time

Non-Hodgkin lymphoma (NHL) is among the most common cancers in the United States. In 2020, an estimated 77,240 Americans will be diagnosed with the disease and about 20,000 people will die from it.1 Seventy-two percent of patients live for at least 5 years after diagnosis.2 However, the success of treatment varies widely across the many subtypes of NHL. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the most common subtype, have a 5-year survival rate of 63% for all disease stages combined. By contrast, follicular lymphoma (FL) has a 5-year survival rate of 88% for all stages combined. Patients with mantle cell lymphoma, one of the more difficult-to-treat subtypes, have an average survival time of less than 5 years.3

But the treatment landscape is transforming across the entire spectrum of NHL. Novel immunotherapies and small molecule inhibitors are offering both previously treated and untreated patients entirely new options and new combinations. At the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, researchers led by Jeremy Abramson, of Massachusetts General Hospital in Boston, provided a compelling overview of these new and upcoming treatments.4 Their overview, published in the ASCO Educational Book, offered a detailed and vital look at the present and future of NHL treatment.

CAR T-cell immunotherapy has been hailed as a major game-changer for some blood cancers.5 For aggressive B-cell lymphomas, such as DLBCL, anti-CD19 chimeric antigen receptor T cells (CAR-T) are a new option for patients who have relapsed following chemoimmunotherapy or autologous stem cell transplant (ASCT). For this patient group, which has a median overall survival of about 4 months, anti-CD19 CAR-T agents have elicited durable remissions in about 40% of patients.5-7 Clinical trial data has led to the approval of axicabtagene, ciloleucel, and tisagenlecleucel by both the US Food and Drug Administration and the European Medicine Agency. CAR T-cells offer curative intent therapy to patients with relapsed DLBCL who are not eligible for stem cell transplant, Dr Abramson told Cancer Therapy Advisor. Previously these patients only had palliative options available.

Some clinicians envision CAR-T as a potential first-line therapy for patients with DLBCL who relapsed after first-line chemoimmunotherapy. These patients, noted Anton Hagenbeek, MD, PhD, professor of Hematology at Amsterdam University Medical Centers, who was not involved with the review paper, represent one of the highest unmet needs in the treatment of lymphoma to date. And Helen Heslop, MD, who directs the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, noted that trials for first-line CAR-T therapy are already underway in acute lymphoblastic leukemia. Not everyone sees this potential. First-line treatment in NHL is generally very effective and much less expensive than CAR T-cells, explained Edward Copelan, MD, who chairs the Department of Hematologic Oncology and Blood Disorders at Carolinas Healthcare System in Charlotte, North Carolina, and who was not an author of the review. Though Dr Copelan emphasized that patients at extremely high risk of relapse following standard immunochemotherapy may respond well to CAR-T therapy.

Dr Abramson and co-authors highlighted a difficult conundrum with regard to DLBCL. Although the addition of rituximab to cyclophosphamide, doxorubicin, hydrochloride, and vincristine sulfate (CHOP) chemotherapy is curative for most patients, the number of patients who may be cured after relapse has declined. Thus improvements in second-line therapy are desperately needed. Several clinical trials are currently evaluating anti CD19 CAR-T for primary refractory or early relapsed aggressive B-cell lymphoma compared with traditional salvage therapy or ASCT. The same approach is being studied for relapsed DLBCL patients who are not transplant candidates.

Whether CAR-T therapy will find a place on the first line of care is another current question. The cost and logistics of CAR-T therapy make it unlikely that this approach will replace R-CHOP as the standard initial treatment, Dr Abramson and colleagues noted. I do not think CAR T-cells will replace frontline chemotherapy, Dr Abramson said. However, the authors note that for patients who do not respond well to initial treatment, such an approach may make sense a possibility that is now being examined in the clinical trial setting. Dr Hagenbeek is more certain about the first-line role for CAR-T therapy, based on the dismal prognosis of DLBCL that is refractory to R-CHOP.

On the subject of CAR-T therapy as first-line therapy, the authors pay special attention to so-called double-hit lymphomas (DHLs), also known as double expressor lymphomas. According to a multicenter study published in 2017, R-CHOP is curative for more patients than conventional wisdom has held.9 Clinical trials are currently investigating the use of anti-CD19 CAR-T early for patients who consistently test positive for disease on PET scans during initial therapy, though Dr Abramson and colleagues call for caution with this approach because the prognostic value of PET/CT scans is controversial. Dr Hagenbeek is optimistic about the potential for CAR-T therapy to improve the prognosis for patients with double- and even triple-hit lymphomas, if applied in the first complete, PET-negative metabolic remission. Because these patients have a relatively small tumor load, this approach could, said Dr. Hagenbeek, completely eradicate minimal residual disease. Its the double-hit patients who Dr Copelan sees as the likeliest candidates for first-line CAR T-cell treatment.

Excerpt from:
Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor

How three equine athletes returned from injury to the show ring

At some point in your horse care journey, youve likely ridden a beautiful round, brought your horse in from turnout, or unloaded him from the trailer and realized something was off. Maybe it was a lame step or the slightest bit of swelling but, either way, it prompted a call to your veterinarian. If you were lucky, the root cause was something minor that would resolve with time off and anti-inflammatories. With the more challenging cases, however, you and your veterinarian might have pursued further diagnostics to determine the cause.

After reaching a diagnosis and settling on a treatment plan, you began the arduous process of healing and rehabilitation. This stage can be trying for even the most patient equestrian. But, with a good equine care team and some time, it can be smooth and fruitful.

To see what effective rehabilitation looks like, we found three real-life examples of equine athletes that made full recoveries from their injuries. Well share each ones diagnostic challenges, rehab modalities, and recovery details.

Chanel, a 10-year-old Quarter Horse mare competing in Western pleasure, had been struggling for years with a nagging intermittent left front lameness. Her owner and veterinarian managed this with routine coffin joint corticosteroid injections for about two years. However, the injections ultimately proved to be ineffective at keeping Chanel completely sound and comfortable, so she was referred to Carrie Schlachter, VMD, Dipl. ACVSMR, who founded and designed Circle Oak Equine Sports Medicines rehabilitation and fitness programs and also founded Animals In Motion, a practice that focuses on integrative sports medicine, rehabilitation, and injury prevention.

The case was pretty routine, says Schlachter. We nerve-blocked (used local anesthesia to numb and pinpoint the painful area) her foot, then we X rayed the area, and the X rays showed some mild abnormality in her coffin bone. We recommended an MRI so we could look at the area more deeply.

The MRI showed that Chanel actually had two injuries to her left front foot. The first was mild coffin bone bruising and remodeling in the area we had been looking at radiographically, Schlachter says. But, on the opposite side of the foot, she also had a collateral ligament injury. Collateral ligaments are located on either side of most joints.

This was the aha! moment, she says: Without the MRI I wouldnt have known about the collateral ligament injury so, because the owners were willing to do the MRI, I was not only able to confirm my diagnosis of the bone bruising and remodeling but I was also able to see the reason for it.

Chanel had likely been compensating for the collateral ligament injury by bearing more weight on one side of her foot, creating the bruising in the coffin bone. The injections helped initially because they suffused the area with steroids, reducing inflammation and allowing her to continue working soundly for a brief period.

With a diagnosis in place, Schlachter recommended putting Chanel in a bar shoe to support and stabilize the collateral ligament and the coffin bone. She and her team also injected the coffin joint and the collateral ligament with autologous protein solution (a biologic therapy that stimulates the bodys production of anti-inflammatory mediators and growth factors) and treated the area with extracorporeal shock wave therapy (believed to improve new blood vessel growth, recruit mesenchymal stem cells, and have pain relieving effects).

Schlachter also recommended for Chanel a controlled exercise program, which she modifies to meet the needs of different injuries and disciplines but typically involves:

Two months post-diagnosis, Schlachter reevaluated Chanel. At that point she was 80-90% better, so we allowed her to be walked under saddle for the next two months, she says. When we looked at her again at the four-month mark, she was 100% sound, so we started her on some trot work.

Once she was sound at the canter, Chanel began working back into training. Eight months post-diagnosis she was still sound and back in the show ring. She is now free of bar shoes, and her only maintenance since recovering has been a round of hock and sacroiliac joint injections to manage normal wear and tear.

Chanel was a wonderful patient, Schlachter says. She is the picture perfect example of what a good diagnosis, good treatment, compliant owners, and a well-behaved horse can do.

Melissa King, DVM, PhD, Dipl. ACVSMR, is an associate professor at the Colorado State University (CSU) Veterinary Teaching Hospital, in Fort Collins, where she specializes in equine sports medicine and rehabilitation. King treated JR, a 16-year-old Thoroughbred who had shown as a four-star eventer. From repetitive use in his job, JR developed an insertional lesion in his deep digital flexor tendon (DDFT, which runs from the knee down the back of the leg and around the navicular bone, attaching to the coffin bone) and a second, discrete tear at the pastern level. This article continues in the August 2020 issue of The Horse: Your Guide to Equine Health Care. Subscribe now and get an immediate download of the issue to continue reading. Current magazine subscribers can access the digital edition here.

View original post here:
The Journey Back: Three Horses Go From Rehab to Recovery - TheHorse.com

Global Canine Stem Cell Therapy Market Size, Status and Forecast 2020-2026

In 2019, the global Canine Stem Cell Therapy Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

Canine Stem Cell Therapy Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Canine Stem Cell Therapy Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The Canine Stem Cell Therapy Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Canine Stem Cell Therapy Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-153387

Top key players @ VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, and Stemcellvet

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Canine Stem Cell Therapy Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Canine Stem Cell Therapy Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Canine Stem Cell Therapy Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Canine Stem Cell Therapy Market?

What are the key market trends impacting the growth of the Global Canine Stem Cell Therapy Market?

What are the challenges to market growth?

Who are the key vendors in the Global Canine Stem Cell Therapy Market?

What are the market opportunities and threats faced by the vendors in the Global Canine Stem Cell Therapy Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Canine Stem Cell Therapy Market;

3.) The North American Canine Stem Cell Therapy Market;

4.) The European Canine Stem Cell Therapy Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Canine Stem Cell Therapy Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-153387

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Read more here:
Global Canine Stem Cell Therapy Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR by Forecast...

It goes by many names: cultured, in vitro, cell-based, cultivated, lab-grown meat, etc. As the names imply, it is a meat alternative made in a lab via animal cells and a cultured medium, like fetal bovine serum or a proprietary mix of sugars and salts. Several companies around the world are promoting this new technique as a way to cultivate a meat alternative that is supposedly cleaner and safer than traditional meat.

(We are only looking at those products that culture cells taken from animals into a new meat-like formulation. There are many other products that culture plant, fungi, or algal cells into a meat substitute, but we are not reviewing them here.)

29 companies are planning to bring lab-cultured meat to market in the form of chicken, beef, pork, seafood, pet food, and beyond. These companies include Memphis Meats, Aleph Farms, Mosa Meat, Meatable, SuperMeat, and Finless Foods. These companies are backed by huge investments from meat industry corporations (Cargill and Tyson), venture capitalist firms (Blue Yard Capital, Union Square Ventures, S2G Ventures, and Emerald Technology Ventures), and billionaires (such as Bill Gates and Richard Branson).

While the hype is certainly there, is lab-cultured meat actually better? Its proponents tout it as an environmentally responsible, cruelty-free, and antibiotic-free alternative to current meat production. While the goal of producing sustainable meat without killing animals is admirable, lab-cultured meat is in its infancy and the science behind the production methods requires more scrutiny.

Of particular concern is the genetic engineering of cells and their potential cancer-promoting properties. To be able to better assess whether the products are being produced by methods that involve genetic engineering and use genetic constructs (called onco-genes, typically used to make stem cells keep growing; this is not a problem for lab experiments, but could be for food products) that might encourage cancer cells, we need more information on how the cells are engineered and kept growing. Many of the companies are claiming this information is confidential and a business secret. These companies are not yet patenting their production processes wherein this information would be more fully disclosed. Some suggest that the production will follow the FDA cell culture guidelines, but theFDAs cell culture guidelines do not apply to this because theyre not designed for food.

To produce lab-cultured meat, many producers extract animal cells from living animals. This is typically done via biopsy, a painful and uncomfortable procedure that uses large needles. If a company could scale up with this method, it would require a consistent supply of animals from which to acquire cells and innumerable painful extractions. To make the cell-based product more consistent, the producer may biopsy the same animal many times for the cells that growing meat requires.

Growing animal cells (typically muscle cells) also requires a growth medium. When lab-cultured meat production first began, companies depended on fetal bovine serum (FBS) as a growth medium. Producing FBS involves extracting blood from the fetus of a pregnant cow when the cow is slaughtered.

Given its high cost, it appears that FBS is usually only used during small-scale lab trials. Additionally, increasing production capacity using FBS comes with its own set of concerns. Even disregarding the high cost of FBS, non-genetically engineered animal muscle cells only proliferate or increase to a certain degree. In order to overcome this limitation, large companies such as Mosa Meats and Memphis Meats claim theyve found an FBS alternative that does not involve animals along with an effective way to expand production. For Memphis Meats, this process involves the utilization of abioreactor and the creation of immortal cell lines.

Curious about how we make our Memphis Meat? See below! #sogood pic.twitter.com/co5d7OY0bI

Memphis Meats (@MemphisMeats) May 8, 2018

These companies are using a bioreactor essentially a very large vessel for containing biological reactions and processes to implement a scaffold-based system to grow meat, which uses a specific structure for cells to grow on and around. The scaffolding helps the cells differentiate into a specific meat-like formation. Researchers cite using cornstarch fibers, plant skeletons, fungi, and gelatin as common scaffold materials. Instead of animal muscle cell precursors (otherwise known as myosatellites), researchers have been using cultured stem cells. This distinction is important because extracted muscle cells will only proliferate to a certain extent. Companies are trying cultured stem cells as an alternative type of cell(s) that could proliferate exponentially so that they could scale up production, and later differentiate the cells into the various cell types that make up animal meat (muscle, fat, and blood cells) in a bioreactor.

In this process, the stem cells still come from animals or animal embryos, but what differentiates the two methods is that in the scaffold-based system, the cells can be genetically engineered to proliferate indefinitely. These cells are otherwise known as pluripotent (which make many kinds of cells, like stem cells) or totipotent (which make every kind of cell, as do embryos). This would greatly expand a companys capacity to make lab-cultured meat, but the methods by which companies make these cells proliferate come with human health and food safety ramifications.

While the FDA has previously reviewed enzymes, oils, algal, fungal, and bacterial products grown in microorganisms, these new animal cell-cultured products are much more complicated in structure and require a more thorough review. The scale required for making lab-cultured meat feasible for mass consumption will be the largest form of tissue engineering to exist and could introduce new kinds of genetically engineered cells into our diets. Further research will also be needed to conrm or dispel uncertainties over various potential safety issues. Candidate topics for research include the safety of ingesting rapidly growing genetically-modied cell lines, as these lines exhibit the characteristics of a cancerous cell which include overgrowth of cells not attributed to the original characteristics of a population of cultured primary cells. If lab-cultured meat enters the market, there are several human health concerns associated with this new production method, specifically that these genetically-modified cell lines could exhibit the characteristics of a cancerous cell.

While these companies dont disclose much to the public about their processing methods, their public patents reveal the creation of oncogenic, or cancer-causing, cells.A Memphis Meats patent on the creation of modified pluripotent cell lines involves the activation or inactivation of various proteins responsible for tumor suppression. Another patent from JUST Inc. describes the utilization of growth factors as part of its growth medium. This process could promote the development of cancer-like cells in lab-cultured meat products. Additionally, it is possible certain growth factors can be absorbed in the bloodstream after digestion.

If they are using stem cells, cell-based meat companies need to pay attention to the risk of cancer cells emerging in their cultures. A research team from the Harvard Stem Cell Institute (HSCI), Harvard Medical School (HMS), and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard has found that as stem cell lines grow in a lab environment, they often acquire mutations in the TP53 (p53) gene, an important tumor suppressor responsible for controlling cell growth and division. Their research suggests that inexpensive genetic sequencing technologies should be used by cell-based meat companies to screen for mutated cells in stem cell cultures so that these cultures can be excluded.

Cancer-causing additives are prohibited in our food supply under the Delaney Clauses in the 1958 Food Additive Amendments and the 1960 Color Additive Amendments to the Federal Food, Drug, and Cosmetic Act (FFDCA). These new rapidly growing cell lines might be considered color additives if they are being used to produce the color in the meat. The federal statutes regulating meat also prohibit the selling of animals with symptoms of illness, such as cancerous cells in meat. Regardless, all of these new ways of making cells that continue to grow or differentiate should require a safety assessment to determine if they contain cancerous cells before they can be sold.

In describing the scaffolding and growth media being used, lab-cultured meat companies need to be fully transparent about what ingredients theyre using. During the above-mentioned industry nonprofits presentation, the presenter suggested the growth media could be composed of a variety of different ingredients like proteins, amino acids, vitamins, and inorganic salts classified under the GRAS (Generally Recognized As Safe) process that allows companies to do their own testing and not submit to a new FDA food additive review. Since companies are not required to fully disclose the composition of their scaffolding or growth media, potentially exposing consumers to novel proteins and allergens, the new mixture of ingredients should be reviewed under a full FDA supervised food additive review, not GRAS.

Another major issue associated with processing methods using cell lines and/or culture medium is contamination. Unlike animals, cells do not have a fully functioning immune system, so there is a high likelihood of bacterial or fungal growth, mycoplasma, and other human pathogens growing in vats of cells. While lab-cultured meat companies emphasize that this type of meat production would be more sterile than traditional animal agriculture, its unknown how that is true without the use of antibiotics or some other pharmaceutical means of pathogenic control.

Based on commentary from various companies, antibiotic usage across the industry is still very unclear. While the industrys promoters have outlined many uses for antibiotics in lab-grown meat production in preventing contamination, they have not disclosed the amount of antibiotics being used in the various processes. Instead, they suggest that because mass production of lab-grown meat will be done in an industrial rather than lab setting, with bioreactors and tanks, there will be higher safety oversight than in medical labs. It is suggested that the many preventative measures in the industry will maintain a sterile boundary and deter antibiotic use in production. It remains a question of how a food production plant would be more sterile than a medical lab.

Some companies, such as Memphis Meats claim they are genetically engineering cell lines to be antibiotic-resistant, which would suggest they plan on using antibiotics, but dont want their meat cells to be affected. Problems with bacterial and viral contamination plague medical cell culture, so they generally use antimicrobials. Still, any large-scale production that requires antibiotic use even if just for a short-term duration should require such lab-cultured meat undergo even stricter USDA drug residue testing, pathogen testing, and FDA tolerance requirements than conventionally-produced meat. Many other companies claim they dont plan to use antibiotics in expanded production which begs the question, in addition to supposed sterile bioreactors, are they using other undisclosed processes to prevent contamination? For example, Future Meat Technologies describes the use of a special resin to remove toxins.

The companies have also not disclosed plans for how they will dispose of the toxins from bioreactors, scaffolding, and culture media like growth factors/hormones, differentiation factors, often including fetal calf serum or horse serum, and antimicrobials (commonly added to cultured cells to prevent bacterial and fungal contamination, particularly in long-term cultures). In conventionally-produced meat, animals dispose of these toxins in their urine and feces. If companies cant find a way for this meat to dispose of these toxins, they could potentially build up within the meat itself. Given the lack of clarity of these companies and their processes, there must be continuous monitoring of the cell lines and growth media/bioreactor for contaminants and some sort of standardization established across the industry to ensure safety.

The industry is new and the exact production process and inputs needed for large-scale, lab-cultured meat production are unknown (or not being disclosed by the companies). It is the responsibility of both FDA and USDA to ensure that all inputs used in production and the final product are safe for human and animal consumption. These agencies must ensure that lab-cultured meat is labeled appropriately, including if any of the product ingredients are genetically modified or if the ingredients are produced using unmodified cells from animals. These agencies must also ensure that this product doesnt introduce new allergens into the food supply, that any hormones or antibiotics used are not found at unsafe levels in the final product, and that the product doesnt contain any compounds or oncogenic (cancer-causing) cells that have not been approved for use in food.

Lab-cultured meat should not be allowed to use the Generally Recognized As Safe (GRAS) regulatory loophole wherein companies can hire their own experts to evaluate their products, often in secret without any notice to the public or FDA. GRAS is an inappropriate designation because the consensus among knowledgeable experts regarding the safety of lab-cultured meat does not yet exist. Instead, FDA should require that lab-cultured meat products be regulated more thoroughly as food additives. Meat companies should submit complete food additive petitions for each of the novel ingredients used to produce these meats as well as a final food approval petition for the entire product. The production facilities, like all meat processing plants, should then have USDA inspectors on-site monitoring the process and inspecting the meat. The USDA announced in August that it will start the process of developing regulations for these new kinds of meat. Adequate regulation will be necessary to address the concerns raised in this blog.

Overall, due to the novel nature of lab-cultured meat, the lack of transparency from the companies involved, and the myriad potential health risks to consumers, rigorous regulation of this product is vitally important. Join Center for Food Safetys mailing list to protect your right to safe food HERE >>

For those of you interested in eating more plant-based, we highly recommend downloading theFood Monster App with over 15,000 delicious recipes it is the largest plant-based recipe resource to help reduce your environmental footprint, save animals and get healthy! And, while you are at it, we encourage you to also learn about theenvironmentalandhealth benefitsof aplant-based diet.

Here are some great resources to get you started:

For more Animal, Earth, Life, Vegan Food, Health, and Recipe content published daily, subscribe to theOne Green Planet Newsletter! Lastly, being publicly-funded gives us a greater chance to continue providing you with high-quality content. Please considersupporting usby donating!

The rest is here:
Is Lab-Grown Meat Healthy and Safe to Consume? - One Green Planet